Divergent Pathways

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: interim CDF recommendations for ADCs, NICE reversal on MRD endpoints, regulatory crises, JSC submissions, and EMA emergency trials. Let's get into it.

SaraStarting with Mirvetuximab soravtansine. The interim CDF recommendation signals conditional reimbursement for ADCs, but the portfolio implications are complex. This creates commercial uncertainty for developers while setting a precedent for accelerated pathways.

MarcusPragmatic, but risky. Interim status means evidence gaps remain. We're building strategies around uncertain final decisions. ADC portfolios now face bifurcated HTA landscapes – conditional approvals in some regions, full reviews elsewhere. Fragmentation is inevitable.

SaraThat's where the evidence strategy fails. Conditional recommendations assume real-world evidence will bridge gaps, but RWE generation takes time. What happens if the final CDF decision shifts? Commercial planning can't operate on moving targets.

MarcusThe alternative is slower access. Interim pathways recognize unmet needs. The portfolio impact is manageable – position ADCs as first-line conditional options while generating confirmatory data. That's better than waiting years for complete dossiers.

SaraMoving to D-VRd NICE reversal. The decision to reject MRD as a cost-effectiveness endpoint reverses earlier guidance. This creates inconsistency in oncology HTA methodologies.

MarcusA necessary correction. MRD endpoints are surrogate measures with unclear real-world value. NICE's reversal aligns with evidence fundamentals – we need hard endpoints like survival or progression-free data for reimbursement decisions.

SaraBut that ignores the reality of modern oncology. MRD demonstrates profound treatment effects. Requiring traditional endpoints delays access for therapies with clear biological impact. The HEOR community must adapt to clinical innovation.

MarcusAdaptation shouldn't compromise evidence rigor. Surrogate endpoints without proven clinical utility distort cost-effectiveness models. NICE's reversal protects HTA integrity, even if it frustrates developers.

SaraNow Avacopan's cross-jurisdictional crisis. Divergent regulatory decisions create HEOR nightmares – one region approves, another restricts, no clear rationale. How do we build global evidence strategies when HTA bodies contradict each other?

MarcusCommercial framing problem. The crisis stems from inconsistent safety interpretations, not evidence gaps. HEOR can't resolve regulatory disagreements. We must develop jurisdiction-specific value narratives that reflect local decision factors.

SaraThat's surrendering to fragmentation. When regulators disagree about fundamental risks, it undermines confidence in HTA processes. The HEOR community should push for harmonized safety assessment frameworks.

MarcusUnrealistic. Regulatory divergence reflects legitimate differences in risk tolerance. Our job is to navigate it, not eliminate it. Focus on transparent benefit-risk communication tailored to each market.

SaraJSC submission window opens June 1. This tight timeline compresses evidence generation for joint clinical assessments. Developers face impossible pressure.

MarcusEfficient resource allocation. The June deadline forces prioritization of high-impact evidence. It streamlines HTA processes by preventing dossier sprawl. Quality improves when resources are concentrated.

SaraBut it ignores RWE generation lags. Real-world studies take months. Compressing timelines means relying on incomplete data, compromising assessment quality. This isn't efficiency – it's rushed decision-making.

MarcusRWE is supplementary. Core evidence must be robust before submission. The timeline pushes developers to prepare properly, not cut corners.

SaraFinally, EMA emergency trial guidance consultation. This expands clinical trial flexibility during crises but raises evidence quality questions.

MarcusEssential agility. Emergency frameworks enable faster data generation for urgent public health needs. The consultation focuses on maintaining scientific rigor within adaptive designs.

SaraBut emergency protocols often relax endpoints or comparators. That creates evidence incompatible with standard HTA requirements. We're generating data that HTA bodies can't use.

MarcusEmergency trials address unmet needs. HTA bodies recognize the evidence limitations. The key is clear communication about study constraints during submissions.

SaraMarcus, these shortcuts undermine HTA credibility. We need consistent evidence standards, not emergency exceptions.

MarcusPragmatism versus purity. In crises, flexibility saves lives. HTA bodies will adapt – they always do.

SaraBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.